ArticleJournal of immunology (Baltimore, Md. : 1950)2013
In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit.
Praveen K Amancha et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
38 papers cite it
this paperpooled itcites it